Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

82.39
-2.5200-2.97%
Post-market: 83.000.6100+0.74%16:58 EDT
Volume:1.60M
Turnover:130.73M
Market Cap:11.61B
PE:-36.08
High:83.76
Open:83.13
Low:80.75
Close:84.91
52wk High:95.49
52wk Low:22.73
Shares:140.86M
Float Shares:122.00M
Volume Ratio:1.57
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:24.93
PE(LYR):-6,757.16

Loading ...

Arrowhead Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow Jones
·
May 09

RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
May 09

Stock Track | Arrowhead Pharmaceuticals Plummets 6.34% Intraday as Q2 Revenue Falls Short of Estimates

Stock Track
·
May 09

Arrowhead price target raised to $90 from $80 at Chardan

TIPRANKS
·
May 08

U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson

Reuters
·
May 08

Arrowhead Pharmaceuticals : Chardan Capital Markets Raises Target Price to $90 From $80

THOMSON REUTERS
·
May 08

Arrowhead reports Q2 EPS (93c), consensus ($1.11)

TIPRANKS
·
May 08

Earnings Flash (ARWR) Arrowhead Pharmaceuticals Posts Q2 Loss $0.93, vs. FactSet Est of $1.10 Loss

MT Newswires Live
·
May 08

Arrowhead swings to FY26 Q2 net loss of $132.73 million; revenue falls to $73.74 million

Reuters
·
May 08

BRIEF-Arrowhead Pharmaceuticals Q2 EPS USD -0.93

Reuters
·
May 08

Arrowhead Pharmaceuticals Q2 Operating Income USD -141.26 Million

THOMSON REUTERS
·
May 08

Corrected-Arrowhead Pharmaceuticals Q2 Net Income USD -132.7 Million (Corrects Amount)

THOMSON REUTERS
·
May 08

Arrowhead Pharmaceuticals Q2 Operating Expenses USD 214.997 Million

THOMSON REUTERS
·
May 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Arrowhead Pharmaceuticals - Madrigal to Pay $25 Mln Upfront and up to $975 Mln in Milestones to Arrowhead

THOMSON REUTERS
·
May 05

Arrowhead Pharmaceuticals - Eligible for Tiered Royalties on Commercial Sales

THOMSON REUTERS
·
May 05

Arrowhead licenses ARO-PNPLA3 MASH drug to Madrigal for USD 25 million upfront

Reuters
·
May 05

Arrowhead Pharmaceuticals to present at BofA Securities 2026 Healthcare Conference

Reuters
·
May 04

Arrowhead Pharmaceuticals Initiated at Overweight by JP Morgan

Dow Jones
·
May 01

Arrowhead says Australia TGA approves REDEMPLO for familial chylomicronemia syndrome

Reuters
·
May 01